Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer

Keyphrases

• Cost-effectiveness Analysis 100%
• Neoadjuvant 100%
• Cisplatin-based Chemotherapy 100%
• Immune Checkpoint Inhibitors 100%
• Muscle-invasive Bladder Cancer 100%
• Recurrence-free Survival 75%
• Incremental Cost-effectiveness Ratio 50%
• Pembrolizumab 50%
• Atezolizumab 37%
• Cost Reduction 25%
• Complete Response Rate 25%
• Neoadjuvant Therapy 25%
• Pathological Complete Response 25%
• Meta-analysis 12%
• Clinical Analysis 12%
• Randomized Clinical Trial 12%
• Analytic Simulation 12%
• Long Follow-up 12%
• Incremental Improvement 12%
• Large Sample Size 12%
• Healthcare Payer 12%
• Incremental Cost 12%
• Simulation Model 12%
• Payer Perspective 12%
• Ipilimumab 12%
• Decision-analytic Model 12%
• One-way Sensitivity Analysis 12%
• Survival Cost 12%
• Nivolumab 12%
• Threshold Analysis 12%
• Gemcitabine Plus Cisplatin 12%
• Average Sale 12%
• Single-arm Clinical Trial 12%
• Probabilistic Sensitivity Analysis 12%
• Price Reduction 12%

Medicine and Dentistry

• Health Care Cost 100%
• Immunity 100%
• Cost-Effectiveness Analysis 100%
• Cisplatin 100%
• Muscle Invasive Bladder Cancer 100%
• Chemotherapy 100%
• Immune Checkpoint Inhibitor 70%
• Recurrence Free Survival 60%
• Pembrolizumab 40%
• Atezolizumab 30%
• Neoadjuvant Therapy 20%
• Clinical Trial 10%
• Health Care 10%
• Randomized Clinical Trial 10%
• Arm 10%
• Meta-Analysis 10%
• Ipilimumab 10%
• Gemcitabine 10%
• Nivolumab 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Cisplatin 100%
• Immune Checkpoint Inhibitor 100%
• Muscle Invasive Bladder Cancer 100%
• Recurrence Free Survival 85%
• Pembrolizumab 57%
• Atezolizumab 42%
• Clinical Trial 14%
• Randomized Clinical Trial 14%
• Gemcitabine 14%
• Ipilimumab 14%
• Nivolumab 14%